KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastoma.
Publication
, Journal Article
Zhang, K; Touat, M; Khasraw, M
Published in: Neuro Oncol
March 7, 2025
Duke Scholars
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
March 7, 2025
Volume
27
Issue
3
Start / End Page
652 / 653
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, K., Touat, M., & Khasraw, M. (2025). KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastoma. Neuro Oncol, 27(3), 652–653. https://doi.org/10.1093/neuonc/noaf001
Zhang, Kenan, Mehdi Touat, and Mustafa Khasraw. “KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastoma.” Neuro Oncol 27, no. 3 (March 7, 2025): 652–53. https://doi.org/10.1093/neuonc/noaf001.
Zhang K, Touat M, Khasraw M. KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastoma. Neuro Oncol. 2025 Mar 7;27(3):652–3.
Zhang, Kenan, et al. “KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastoma.” Neuro Oncol, vol. 27, no. 3, Mar. 2025, pp. 652–53. Pubmed, doi:10.1093/neuonc/noaf001.
Zhang K, Touat M, Khasraw M. KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastoma. Neuro Oncol. 2025 Mar 7;27(3):652–653.
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
March 7, 2025
Volume
27
Issue
3
Start / End Page
652 / 653
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences